Table 3. Proportion of patients who underwent adequate lymph node dissection * and had nodal metastases by tumor extension and tumor size (date of diagnosis 2004-2012)a.
| WDNET | MHT | |||
|---|---|---|---|---|
| No. LN-positive/No. patients examined (%) | No. LN-positive/No. patients examined (%) | |||
| T stage | n=199 | n=483 | ||
| T1 | T1a | 4/42 (9.5) | 18.2 (8/44) | |
| T1b | 36/63 (57.1) | |||
| T2 | 37/51 (72.5) | 18.5 (5/27) | ||
| T3 | 79.1 (19/24) | 22.8% (64/280) | ||
| T4 | 78.9 (15/19) | T4a | 51.5 (33/64) | |
| T4b | 88.1 (59/67) | |||
| T4 NOS | 100.0 (1/1) | |||
| Tumor size | n=194 | n=316 | ||
| ≤10 mm | 11.6 (5/43) | 10.4 (5/48) | ||
| 11–20 mm | 56.8 (42/74) | 32.9 (27/82) | ||
| >20 mm | 76.6 (59/77) | 46.2 (86/186) | ||
Abbreviations: WDNET: well-differentiated neuroendocrine tumor; MHT: mixed histology tumor; LN: lymph node; NOS: not otherwise specified.
aTumor size and tumor extension data are based only on pathologic information.
* Patients were counted as node negative if they had adequate lymphadenectomy with 12 negative lymph node.